Brain Cancer section

Brain Cancer News and Features

Personalized Medicine Approach Not Straightforward in Glioblastoma

Personalized Medicine Approach Not Straightforward in Glioblastoma

The role of antiangiogenic agents continues to evolve in the treatment of CNS cancers, attendees were told in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting.

New WHO Glioma Classification Can 'Optimize Patient Treatment Going Forward'

New WHO Glioma Classification Can 'Optimize Patient Treatment Going Forward'

The 2016 WHO Classification of Infiltrating Gliomas alters diagnostic criteria, providing the basis for clinical trial inclusion or exclusion based on an integrated diagnosis and setting the stage for all future research, according to a summary of 4 posters related to CNS biomarkers presented at the ASCO 2016 Annual Meeting.

Eight Immune Genes Identified As Playing a Role in Glioblastoma

Eight Immune Genes Identified As Playing a Role in Glioblastoma

Discovery might eventually lead to better treatment for glioblastoma multiforme

Clinical Results Matches Development Locale With Subtype of Disease in Glioblastoma

Clinical Results Matches Development Locale With Subtype of Disease in Glioblastoma

Results from a recent clinical study show that distinct subtypes of glioblastoma tend to develop in different regions of the brain.

Phase 1 Study Results Show CAR T-cell Therapy Promising in Solid Brain Tumors

Phase 1 Study Results Show CAR T-cell Therapy Promising in Solid Brain Tumors

Glioblastoma tumors were successfully infiltrated by investigational CAR therapy with an acceptable safety profile.

Brain Cancer Videos

Brain Cancer Clinical Trials

DECT Trial Results Show Trastuzumab Plus Anthracyclines Are Efficacious in HER2+ Breast Cancer

Results from the DECT trial indicate that a combination of epirubicin and trastuzumab improved outcomes in patients with HER2-positive breast cancer.

Outcomes in Clinical Trials Using Precision Medicine Demonstrate Effectiveness of Modality in Patients With Cancer

A meta-analysis of hundreds of cancer clinical trials revealed that therapeutic approaches using precision medicine had improved responses and longer disease remission, even in phase I trials.

Surrogate End Points Are Poor Predictors of Survival in Cancer Drug Approval

US FDA standards demand that surrogate end points used in clinical trials be "reasonably likely to predict" survival for accelerated approval, or be established proxies for survival for traditional approval; however, surrogate end points used frequently lack formal study.

Daratumumab in Combination With Standard-of-Care Treatment Significantly Improves Outcomes in Patients With Multiple Myeloma

Daratumumab in combination with the standard-of-care treatment regimen reduced risk of disease progression or death by 63% compared with the standard-of-care regimen alone in patients with multiple myeloma who had received at least 1 prior line of therapy.

Vaccine Enters Phase I Study for Safety and Effectiveness in Multiple Myeloma

A third clinical trial is beginning for phase I testing of SurVaxM, a cancer vaccine. This trial tests for safety and effectiveness of the vaccine in combination with lenalidomide as maintenance therapy for adults with multiple myeloma.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs